XNASTRVI
Market cap341mUSD
Jan 15, Last price
3.82USD
1D
-2.80%
1Q
22.44%
IPO
-53.58%
Name
Trevi Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
61.68%
Rev. gr., 5y
%
Revenues
0k
Net income
-29m
L-0.30%
CFO
-32m
L+12.55%
Earnings
Mar 18, 2025
Profile
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 34,046 | 29,950 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (34,046) | (29,950) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (32) | (36) | ||||||
Tax Rate | ||||||||
NOPAT | (34,014) | (29,914) | ||||||
Net income | (29,065) -0.30% | (29,152) -14.11% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 1,710 | 105,410 | ||||||
BB yield | -1.29% | -84.62% | ||||||
| Debt | ||||||||
Debt current | 612 | 7,025 | ||||||
Long-term debt | 2,370 | 2,180 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | 3 | |||||||
Net debt | (79,989) | (3,384) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (31,710) | (28,175) | ||||||
CAPEX | (137) | (159) | ||||||
Cash from investing activities | 59,428 | (107,373) | ||||||
Cash from financing activities | (7,910) | 111,307 | ||||||
FCF | (35,379) | (29,924) | ||||||
| Balance | ||||||||
Cash | 82,971 | 12,589 | ||||||
Long term investments | ||||||||
Excess cash | 82,971 | 12,589 | ||||||
Stockholders' equity | (239,095) | (210,131) | ||||||
Invested Capital | 323,286 | 326,771 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 99,033 | 64,542 | ||||||
Price | 1.34 -30.57% | 1.93 146.74% | ||||||
Market cap | 132,705 6.53% | 124,566 597.20% | ||||||
EV | 52,716 | 121,182 | ||||||
EBITDA | (33,923) | (29,907) | ||||||
EV/EBITDA | ||||||||
Interest | 391 | 780 | ||||||
Interest/NOPBT | ||||||||